The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 07, 2022
Filed:
Feb. 11, 2019
H. Lundbeck A/s, Valby, DK;
Maria-Cristina Loomis, Bothell, WA (US);
Leon Garcia-Martinez, Woodinville, WA (US);
Benjamin H. Dutzar, Seattle, WA (US);
Daniel S. Allison, Lake Forest Park, WA (US);
Katherine Lee Hendrix, Bothell, WA (US);
Ethan W. Ojala, Snohomish, WA (US);
Pei Fan, Bothell, WA (US);
Jeffrey T. L. Smith, Dublin, IE;
John A. Latham, Seattle, WA (US);
Charlie Karasek, Seattle, WA (US);
Jenny Mulligan, Lake Forest Park, WA (US);
Michelle Scalley-Kim, Seattle, WA (US);
Erica Stewart, Seattle, WA (US);
Vanessa Lisbeth Rubin, Seattle, WA (US);
Jens J. Billgren, Seattle, WA (US);
H. LUNDBECK A/S, Valby, DK;
Abstract
The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.